{"product_id":"the-semaglutide-revolution-market-study-1","title":"The Semaglutide Revolution Market Study","description":"\u003cp\u003eFew pharmaceuticals have changed the world like glucagonlike peptide-1 (GLP-1) agonists. Originally approved and marketed as tools to lower blood sugar in diabetics, the publication and promotion of off-label weight loss capabilities of brands including Ozempic, Wegovy, Rybelsus (semaglutide), Victoza (Liraglutide), and Zepbound and Mounjaro (Tirzepatide), led to worldwide shortages for diabetic patients — and billions of dollars in sales for key makers Eli Lilly and Novo Nordisk.\u003c\/p\u003e","brand":"Medical Insight","offers":[{"title":"Default Title","offer_id":47017551659108,"sku":null,"price":5000.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0594\/8909\/1684\/files\/SemaglutideStudyCover2025.jpg?v=1759862775","url":"https:\/\/medical-insight-3420.myshopify.com\/products\/the-semaglutide-revolution-market-study-1","provider":"Medical Insight","version":"1.0","type":"link"}